Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $18.70 Million

Share on StockTwits

Brokerages predict that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report sales of $18.70 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Alnylam Pharmaceuticals’ earnings. The lowest sales estimate is $6.47 million and the highest is $29.10 million. Alnylam Pharmaceuticals posted sales of $17.10 million in the same quarter last year, which suggests a positive year over year growth rate of 9.4%. The company is expected to issue its next quarterly earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full year sales of $93.71 million for the current fiscal year, with estimates ranging from $67.41 million to $128.21 million. For the next financial year, analysts anticipate that the business will post sales of $177.14 million, with estimates ranging from $97.27 million to $306.46 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the consensus estimate of ($1.74) by $0.11. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The company had revenue of $29.91 million for the quarter, compared to analyst estimates of $16.96 million. During the same quarter in the prior year, the company earned ($1.07) EPS. The firm’s revenue for the quarter was up 87.8% compared to the same quarter last year.

Several equities research analysts recently commented on ALNY shares. BidaskClub upgraded Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 23rd. Cantor Fitzgerald started coverage on Alnylam Pharmaceuticals in a research report on Monday, October 1st. They set an “overweight” rating and a $135.00 target price on the stock. JMP Securities set a $198.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 28th. Needham & Company LLC set a $152.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 27th. Finally, ValuEngine upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 28th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and sixteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $144.17.

Shares of Alnylam Pharmaceuticals stock opened at $78.59 on Friday. Alnylam Pharmaceuticals has a one year low of $78.29 and a one year high of $153.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.22 and a current ratio of 13.22. The stock has a market cap of $8.81 billion, a P/E ratio of -14.63 and a beta of 2.56.

In other news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $120.00, for a total value of $300,000.00. Following the completion of the sale, the chief operating officer now directly owns 1,916 shares of the company’s stock, valued at $229,920. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO John Maraganore sold 50,000 shares of the stock in a transaction that occurred on Wednesday, July 25th. The stock was sold at an average price of $105.39, for a total value of $5,269,500.00. Following the completion of the sale, the chief executive officer now directly owns 201,297 shares of the company’s stock, valued at $21,214,690.83. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of ALNY. Point72 Asset Management L.P. raised its stake in shares of Alnylam Pharmaceuticals by 49.4% in the second quarter. Point72 Asset Management L.P. now owns 1,356,408 shares of the biopharmaceutical company’s stock worth $133,593,000 after purchasing an additional 448,362 shares during the last quarter. American Century Companies Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $42,128,000. Baillie Gifford & Co. increased its position in shares of Alnylam Pharmaceuticals by 10.4% during the second quarter. Baillie Gifford & Co. now owns 4,231,881 shares of the biopharmaceutical company’s stock valued at $416,798,000 after acquiring an additional 397,668 shares during the last quarter. Legal & General Group Plc increased its position in shares of Alnylam Pharmaceuticals by 227.4% during the first quarter. Legal & General Group Plc now owns 348,570 shares of the biopharmaceutical company’s stock valued at $41,515,000 after acquiring an additional 242,098 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its position in shares of Alnylam Pharmaceuticals by 333.0% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 302,695 shares of the biopharmaceutical company’s stock valued at $29,812,000 after acquiring an additional 232,782 shares during the last quarter. 93.41% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.